BioSpace News Archive

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced data base lock for its Phase 1b CLEAR clinical study to evaluate the effect of intranasal REVTx-99b on nasal challenge allergen in participants with allergic rhinitis to rye grass pollen.

Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared two posters that were presented at the Controlled Release Society (CRS) 2022 Annual Meeting, which is being held July 11-15, 2022, in Montreal, Canada.

Today, the U.S. Food and Drug Administration announced the availability of educational resources for parents and caregivers with questions about using the hundreds of millions of bottles worth of imported infant formula headed to the U.S.

Global health services company Cigna Corporation (NYSE:CI) will release its second quarter 2022 financial results on Thursday, August 4, 2022, and will host a conference call the same day.

PathAI, a global leader in AI-powered pathology, today announced that it has appointed Brandon Eldredge as Chief Financial Officer.

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced today first surgeries leveraging the power of the Newton™ Knee , featuring new, user-friendly instrumentation and a modernized graphical user interface.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” the “Company”), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage

ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) (“ScreenPro” or the “Company”) is pleased to announce that the Company has administered approximately 21,500 Covid-19 tests for the month of June and provided testing services to twenty-three (23) film and production companies in June from some of the most prominent companies in the North American film industry.

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark” or the “Company”) an oncology-focused company with advanced near-to-market liquid biopsy diagnostic technologies is pleased to announce today its financial results and recent corporate highlights for the full-year ended March 31, 2022

VistaPath, the leading provider of artificial intelligence (AI)-based, data-driven pathology processing platforms, today announced that VistaPath Sentinel was validated in a clinical setting after a collaboration with PathAI, a global leader in AI-powered pathology.